ArticleBMC psychiatry2026
Treatment of therapy-resistant OCD with application of transcranial alternating current stimulation (tACS): a case series.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObsessive-compulsive disorder (OCD) is a chronic condition that significantly impacts patients’ lives. Various treatments, including pharmacological, behavioral, and brain stimulation methods, are employed. Recent studies indicate that transcranial alternating current stimulation (tACS) effectively alleviates OCD symptoms, warranting further investigation into its therapeutic potential.
methodsA 4-week study at the Tertiary Center of Psychiatry and Behavioral Science in Southern Iran evaluated the effectiveness of tACS for treating OCD in participants aged 18–60. The treatment involved bi-weekly sessions targeting frontal brain areas, assessing various psychological metrics. Results indicated a significant improvement in specific measures. All participants met predefined therapy-resistance criteria based on documented non-response to evidence-based pharmacotherapy and/or structured CBT prior to enrolment.
resultsNinety-five patients were screened, and five eligible participants with OCD (ages 18–46; four female) completed the intervention. All had severe baseline symptoms (Y-BOCS ≥ 23). Obsessive–compulsive symptoms showed consistent improvement, with mean Y-BOCS decreasing from 28.4 ± 4.16 to 18.4 ± 6.34 (35.2% reduction). CGI-S scores declined from 5.4 ± 0.89 to 4.6 ± 1.14, and the mean CGI-I score was 2.6, indicating notable clinical improvement. Affective symptoms improved substantially: total DASS-21 scores decreased by 46.4%, including reductions in stress, depression, and anxiety. SBQ-R scores also declined (− 16.7%). Cognitive performance showed generally favorable trends, with improvement in TOLT planning scores. No major adverse effects were reported, aside from mild irritation and brief flashing sensations.
conclusionsOur pilot study on therapy-resistant OCD with tACS yields promising initial results and safety. However, limitations stress cautious interpretation, necessitating larger, controlled trials for validation and refinement. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.